2 results
Positive opinionRecruiting
Primary Objective: - Achieving an event-free survival, which is not inferior to the ML-DS 2006 trial (87±3%) Secondary Objective(s): - Reduction of toxicity: severe adverse events (CTCAE v4.0 grade III or higher) - Evaluation of…
Not applicableOther
The study objective of the trial was to test the hypothesis that treatment with mepolizumab only affects inflammatory eosinophils whereas treatment with benralizumab affects both inflammatory and resident eosinophils.